October 14, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
DEFINE-HF
Issue: October 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Researchers compared dapagliflozin (Farxiga, AstraZeneca) vs. placebo for HF-specific biomarkers, symptoms, health status and quality of life in patients with HF with reduced ejection fraction with or without diabetes.